| scholarly article | Q13442814 |
| P50 | author | Waun Ki Hong | Q17198867 |
| Christopher Amos | Q64853144 | ||
| Margaret Spitz | Q87847501 | ||
| P2093 | author name string | Qingyi Wei | |
| Xifeng Wu | |||
| Carol J Etzel | |||
| Qiong Dong | |||
| P2860 | cites work | Harvard report on cancer prevention volume 4: Harvard Cancer Risk Index. Risk Index Working Group, Harvard Center for Cancer Prevention | Q33908154 |
| Variations in lung cancer risk among smokers. | Q34184504 | ||
| A method of comparing the areas under receiver operating characteristic curves derived from the same cases | Q34272510 | ||
| Genetic susceptibility to lung cancer: the role of DNA damage and repair. | Q35199045 | ||
| The LLP risk model: an individual risk prediction model for lung cancer | Q36614749 | ||
| Interplay between mutagen sensitivity and epidemiological factors in modulatinglung cancer risk. | Q40458175 | ||
| Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study | Q40845183 | ||
| Development and field-test validation of an assay for DNA repair in circulating human lymphocytes | Q41138849 | ||
| Inactivation of plasmid reporter gene expression by one benzo(a)pyrene diol-epoxide DNA adduct in adult rat hepatocytes. | Q45939928 | ||
| Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. | Q45990033 | ||
| Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). | Q46576237 | ||
| Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. | Q51898509 | ||
| Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. | Q51933968 | ||
| Sensitivity to genotoxic effects of bleomycin in humans: possible relationship to environmental carcinogenesis. | Q53516240 | ||
| Prospective breast cancer risk prediction model for women undergoing screening mammography | Q80216670 | ||
| A risk model for prediction of lung cancer | Q80242314 | ||
| Validation of a model of lung cancer risk prediction among smokers | Q83276607 | ||
| P433 | issue | 4 | |
| P921 | main subject | lung cancer | Q47912 |
| P304 | page(s) | 250-254 | |
| P577 | publication date | 2008-09-01 | |
| P1433 | published in | Cancer Prevention Research | Q2665103 |
| P1476 | title | An expanded risk prediction model for lung cancer | |
| P478 | volume | 1 |
| Q57794234 | A multi-parameterized artificial neural network for lung cancer risk prediction |
| Q34966064 | A risk model for lung cancer incidence |
| Q35688591 | A simple model for predicting lung cancer occurrence in a lung cancer screening program: The Pittsburgh Predictor |
| Q88034408 | Applying Risk Prediction Models to Optimize Lung Cancer Screening: Current Knowledge, Challenges, and Future Directions |
| Q33936367 | Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention |
| Q52661245 | Associations between expression levels of nucleotide excision repair proteins in lymphoblastoid cells and risk of squamous cell carcinoma of the head and neck. |
| Q38844239 | Biomarker development in the precision medicine era: lung cancer as a case study. |
| Q26747784 | Biomarkers of risk to develop lung cancer in the new screening era |
| Q90541051 | Blood based biomarkers beyond genomics for lung cancer screening |
| Q39612965 | Bridging the etiologic and prognostic outlooks in individualized assessment of absolute risk of an illness: application in lung cancer |
| Q37111529 | Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines |
| Q36882598 | Combining Telomerase Reverse Transcriptase Genetic Variant rs2736100 with Epidemiologic Factors in the Prediction of Lung Cancer Susceptibility |
| Q58129895 | Drug response prediction model using a hierarchical structural component modeling method |
| Q37246043 | Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers |
| Q37322288 | Emerging molecular technologies for identifying the risk of second cancers |
| Q86906665 | Epidemiology of Lung Cancer |
| Q30417598 | Existing general population models inaccurately predict lung cancer risk in patients referred for surgical evaluation |
| Q97526719 | Extracellular vesicles: novel communicators in lung diseases |
| Q92310082 | Feasibility of lung cancer prediction from low-dose CT scan and smoking factors using causal models |
| Q34976530 | Fifty years of tobacco carcinogenesis research: from mechanisms to early detection and prevention of lung cancer |
| Q26852320 | Genetic susceptibility to lung cancer--light at the end of the tunnel? |
| Q35511905 | Identifying patients with suspected lung cancer in primary care: derivation and validation of an algorithm |
| Q36992197 | Incorporating epistasis interaction of genetic susceptibility single nucleotide polymorphisms in a lung cancer risk prediction model |
| Q26995495 | Lung cancer chemoprevention: current status and future prospects |
| Q35090585 | Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. |
| Q47819582 | Lung cancer screening-low dose CT for lung cancer screening: recent trial results and next steps. |
| Q26829339 | Lung cancer screening: past, present and future |
| Q38155065 | Lung cancer screening: review and performance comparison under different risk scenarios |
| Q24630167 | Lung cancer: epidemiology, etiology, and prevention |
| Q24625044 | Lung carcinogenesis by tobacco smoke |
| Q37402403 | Molecular targets for cancer chemoprevention |
| Q37514797 | Non-invasive lung cancer diagnosis by detection of GATA6 and NKX2-1 isoforms in exhaled breath condensate |
| Q37643215 | Oral Cell DNA Adducts as Potential Biomarkers for Lung Cancer Susceptibility in Cigarette Smokers |
| Q36158678 | Pharmacogenomics of platinum-based chemotherapy in NSCLC |
| Q30610197 | Predicting lung cancer prior to surgical resection in patients with lung nodules |
| Q37733169 | Predicting the future of genetic risk prediction |
| Q39355104 | Prediction of lung cancer incidence on the low-dose computed tomography arm of the National Lung Screening Trial: A dynamic Bayesian network. |
| Q33599090 | Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy |
| Q64928296 | Prediction of the 1-Year Risk of Incident Lung Cancer: Prospective Study Using Electronic Health Records from the State of Maine. |
| Q41237900 | Predictive Accuracy of the PanCan Lung Cancer Risk Prediction Model -External Validation based on CT from the Danish Lung Cancer Screening Trial |
| Q28392363 | Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium |
| Q33764913 | Reduced DNA repair capacity for removing tobacco carcinogen-induced DNA adducts contributes to risk of head and neck cancer but not tumor characteristics |
| Q40256963 | Reduced mRNA expression of nucleotide excision repair genes in lymphocytes and risk of squamous cell carcinoma of the head and neck |
| Q92477500 | Risk prediction models for lung cancer: Perspectives and dissemination |
| Q36334146 | Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study |
| Q26799888 | Screening for lung cancer using low-dose computed tomography: concerns about the application in low-risk individuals |
| Q30543321 | Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. |
| Q37594556 | Selection criteria for lung-cancer screening |
| Q36335248 | Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma |
| Q35208501 | The BATTLE to personalize lung cancer prevention through reverse migration |
| Q38133416 | The contribution of risk prediction models to early detection of lung cancer |
| Q35805572 | The cytokinesis-blocked micronucleus assay as a strong predictor of lung cancer: extension of a lung cancer risk prediction model |
| Q36453693 | The effect of metformin and thiazolidinedione use on lung cancer in diabetics |
| Q38203985 | The epidemiology and clinical implications of genetic variation in prostate cancer |
| Q37250499 | The field of tissue injury in the lung and airway |
| Q34175634 | The potential for using risk models in future lung cancer screening trials |
| Q28388931 | Updates and controversies in the rapidly evolving field of lung cancer screening, early detection, and chemoprevention |
| Q39009285 | Visual assessment of early emphysema and interstitial abnormalities on CT is useful in lung cancer risk analysis |
| Q35048580 | What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK? |
Search more.